ABOUT 22nd_BEF
> REGISTRATION​​​
> PRESENTERS​
​> SPONSORS​​​
> SUPPORTERS​​
> NETWORKING​​​
> ACCOMMODATION​​​

> ABOUT LAST YEAR

In-person presenters:

20-minute Presenters

Addex Therapeutics Ltd.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs.

www.addextherapeutics.com/en/

BioInvent International AB

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit.

www.bioinvent.com

GeNeuro SA

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of neurodegenerative diseases, such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) and, more recently, neuropsychiatric syndromes in Post-COVID.

www.geneuro.com

Glycostem Therapeutics B.V.

Glycostem is focused on the development of first and second generation stem cell-derived Natural Killer cells (NK cells) as a therapeutic asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells. NK cells play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM). When the cells of a patient’s immune system are not strong enough to fight cancer cells, the infusion of NK cells collected from a donor may contribute to a better response by the patient's immune system.

Thanks to its nine patent families, longstanding technical expertise and resources, as well as Orphan Drug Designation, Glycostem has secured a leadership position in the global NK cell market.

www.glycostem.com

Immunicum AB

Immunicum is leveraging its unparalleled expertise in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.

www.immunicum.com

IO Biotech ApS

IO Biotech is located in Copenhagen, Denmark and was founded in December 2014 as a spin-out from the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital, Denmark.

IO Biotech has an experienced management team within the immuno-oncology field and a world-class advisory board. IO Biotech is a privately held company with a solid financial position and recently raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare Investments, and other new investors joining the round included Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners1, PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital, with the participation of existing investors Novo Seeds, Lundbeckfonden Emerge and Sunstone Life Science Ventures.

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®. IO Biotech has a proven track record of progressing preclinical and clinical compounds.

IO102 and IO103 are IO Biotech’s lead immuno-oncology candidates. Both compounds are based on IO Biotech’s proprietary T-win® technology platform which enables the identification of compounds with a dual mechanism of action targeting and directly killing immunosuppressive cells and tumor cells while indirectly activating other T-effectors, leading to strong anti-tumor responses without adding additional safety concern. Specifically, IO102 and IO103 are first-in-class, immune modulatory vaccines designed to engage and activate IDO and PD-L1 specific human T-cells.

The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

www.iobiotech.com

Macomics Ltd.

Macomics is developing precision medicines to modulate macrophages for the treatment of cancer. Our vision is to develop new approaches to target the immunosuppressive tumour microenvironment, that exploits disease specific macrophage biology to harness the power of the immune system.

We have a portfolio of antibody programs progressing towards clinic and continue to identify new therapeutic targets through it's proprietary target identification approach. By combining analysis of human disease tissue, in silico data mining, and functional data from state-of-the-art cellular models we continue to identify and validate new drug targets in diseases where macrophages play a central role.

The company was co-founded in 2020 by Prof Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology.

www.macomics.com/

Marker Therapeutics, Inc.

Marker Therapeutics (Marker) is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Marker developed lead product candidates from MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

www.markertherapeutics.com/

NH TherAguix SAS

NH TherAguix is a clinical stage pharmaceutical company developing innovative nanomedicine that improve radiation therapy benefits without modifying current clinical workflows. Our leading product, AGuIX®, is a nanoparticle designed to improve the localization of solid tumors and the outcomes of radiation therapy by a unique intravenous injection.

http://nhtheraguix.com/

NOXXON Pharma AG

NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.

After NOXXON’s lead program NOX-A12 delivered final top-line data with encouraging overall survival and safety profile from a combination trial with an anti-PD-1 immuno-oncology checkpoint inhibitor in metastatic colorectal and pancreatic cancer patients in September 2020, the company announced in July 2021 its upcoming Phase 2 study to further evaluate safety and efficacy of NOX-A12 in combination with anti-PD-1 and two different chemotherapy regimens as second-line therapy in patients with  pancreatic cancer.

The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. An ongoing trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit from standard chemotherapy has delivered interim data from the low- and mid-dose cohorts showing consistent tumor reductions. The read-out from the third high-dose cohort is expected in early 2022.

The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic and NOXXON plans to develop NOX-E36 in patients with solid tumors.

www.noxxon.com/

Oryzon Genomics, S.A.

Oryzon is a public clinical stage biopharmaceutical company focused in Epigenetics. Oryzon’s LSD1 program has rendered two compounds, vafidemstat and iadademstat, in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets.

Iadademstat (ORY-1001) is a potent and selective inhibitor of the epigenetic enzyme Lysine-specific histone demethylase 1A (LSD1). It has a strong differentiating effect in hematologic cancers. LSD1 inhibition has been proposed also as a valid therapeutic approach in some solid tumors. Iadademstat has been tested in four trials (two in monotherapy in SCLC and AML, and two in combination, in SCLC and AML) in +100 patients. In the AML combination study, ALICE, we reported at EHA21 updated 30-month data with encouraging signals of efficacy with an objective response rate (“ORR”) of 83%. Plans for regulatory studies in blood and solid cancers are underway.

Vafidemstat (ORY-2001) is the first histone demethylase inhibitor in clinical development in CNS with a solid safety package build-on data of +300 patients. We reported final data from our Phase IIa REIMAGINE basket trial of vafidemstat in ASD, ADHD and BPD. The data demonstrated control of agitation and aggression, particularly in the BPD population, where we observed an overall improvement in the global disease scale BPDCL and a reduction in suicidal ideation. We are advancing vafidemstat into Phase IIb trials in BPD (PORTICO trial) and schizophrenia (EVOLUTION trial). After receiving regulatory clearance, both trials are now recruiting patients. We plan also to start in 2022 the first personalized medicine trial, HOPE, in Kabuki Syndrome patients with confirmed KMT2D pathogenic mutations.

www.oryzon.com/en

Revolo Biotherapeutics

We are on a mission to change the lives of people with autoimmune and allergic diseases by developing therapies that reset the immune system to achieve long-term disease remission. Revolo Biotherapeutics (“Revolo Bio”) has a global footprint, with headquarters in both New Orleans, LA, in the US, and London in the United Kingdom.

Our team of accomplished industry professionals has a track record of success in funding and executing drug development and commercialization plans. We are ready to revolutionize autoimmune and allergic disease treatment!

www.revolobio.com/

STALICLA SA

STALICLA is a Swiss clinical stage biotech company deploying and applying a first in class discovery platform to bring precision medicine to patients with Neurodevelopmental Disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).

STALICLA has assembled a world-class team of 26 seasoned drug developers, clinicians, data scientists and computational biologists.
DEPI, the company's NDD precision medicine platform leveraging on ML and transcriptomics technology, has reached proof of concept for its capacity to characterize biologically similar subgroups of patients within highly variable populations of patients with neurodevelopmental disorders, and to further identify tailored treatment candidates.
To further advance its drug discovery platform and pipeline, STALICLA has established strong networks within top tier research and clinical centers in the United States and Europe.

STALICLA currently has one precision medicine candidate in the clinic and plans to bring two assets into Phase 2 in 2022.

The company is also advancing collaborative alliances with strategic third party pipelines.

STALICLA has raised USD 27M to date and is rapidly scaling its platform and clinical development activity. For more information, please visit company's website.

www.stalicla.com

Ultimovacs ASA

Ultimovacs (Euronext Oslo Stock Exchange: ULTI.OL) is a Norwegian biotech Company that is pursuing several Phase II clinical development trials in a number of cancer indications. The company is advancing its proprietary peptide-based universal cancer vaccine program, UV1. UV1 induces a specific T cell response against the universal cancer antigen telomerase (hTERT) and is made up of long, synthetic peptides shown to induce CD4+ T cells displaying a Th1 cytokine profile. With over 85% of tumors expressing hTERT at a high level, UV1 has the potential to treat a broad range of cancer indications.

To date, Ultimovacs has conducted multiple Phase I studies in different cancer indications with different inhibitor combinations, confirming the safety and tolerability of its proprietary vaccine. The company announced the initiation of four Phase II triple combination studies:

• INITIUM: Randomized Ultimovacs sponsored Phase II combination trial in 1st line treatment of patients with metastatic malignant melanoma
• NIPU: Sponsored by Oslo University Hospital in collaboration with Bristol-Myers Squibb randomized Phase II combination trial in 2nd line malignant pleural mesothelioma
• DOVACC: Randomized Phase II clinical trial in collaboration with European Network of Gynaecological Oncological Trial Groups (ENGOT) and AstraZeneca to evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with durvalumab and olaparib in patients with relapsed ovarian cancer
• FOCUS: Randomized Phase II clinical trial that will evaluate the Ultimovac's proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.

www.ultimovacs.com/

10-minute Presenters

Acthera Therapeutics Ltd.

Acthera Therapeutics is a Swiss biotech company, developing a unique and innovative type of liposomes, for the targeted and controlled delivery of drugs. Based on a patented synthetic lipid, we produce Hard-Shelled Liposomes (HSL) that have a dodecahedric shape, with faces and edges, a unique characteristic among liposomes. This gives the HSL a strong differentiator: they are mechanosensitive. When submitted to appropriate pressure, HSL release their payload, and this unique ability allows the controlled and targeted delivery of drugs. This is the ideal way to maximize the therapeutic potential of multiple drugs, increasing efficacy by better targeting the drug to its target and reducing unwanted systemic effects.  

The combination of HSL with various payloads and specific release triggers opens a large field of therapeutic opportunities in many clinical indications. Multiple payloads can be encapsulated, from small molecules, to RNA and peptides. The encapsulation of the therapeutic agents is a protection against metabolism or excretion, until the drug is locally released to its cellular or tissular/organ target, optimizing the PK/PD parameters.

Various mechanical triggers can activate the release of the HSL payload. High shear stress associated with a pathological vascular occlusion is an internal trigger that can be used to deliver active drugs at the site of an acute thrombosis, in acute myocardial infarction or acute ischemic stroke. External triggers, such as ultrasound or laser light, applied to target specific body locations or organs can have the same effect, and can be associated.

The HSL-payload-trigger combination is a unique way to deliver drugs WHERE and WHEN they are needed, from cardiovascular to oncologic diseases. It is a very powerful instrument to increase the therapeutic effectiveness of many drugs, whose use is still limited by their unfavorable efficacy:safety profile. For the benefit of patients!

www.acthera-therapeutics.com/

Apaxen S.A.

Apaxen is a privately-held biotechnology company developing innovative treatments for patients with diseases that depend on chronic NLRP3 Inflammasome activation. Our primary focus is on treatment of pulmonary arterial hypertension (PAH)

We develop first-in-class small molecule inhibitors of NLRP3 Inflammasome activation, a key driver of inflammation in many diseases. Our drugs work by neutralizing Macrophage Migration Inhibitory Factor (MIF), a protein which is required for the construction and activation of NLRP3 Inflammasomes.

Apaxen’s lead compound, MFC-1040 is being developed as a “disease modifying” treatment of pulmonary arterial hypertension (PAH), a rare and fatal inflammatory disease, with a strong medical need since approved treatments are symptomatic vasodilators and associated with low median survival.

Our approach is a platform for the discovery and development of a pipeline of MIF/Inflammasome inhibitors for treatment of many inflammatory and autoimmune diseases, inflammaging related diseases and cancer.

Apaxen has its headquarters in Gosselies (Belgium), at the Biopark Charleroi Brussels South.

www.apaxen.com/

Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015 in Germany, is a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies. The company develops a therapy platform to treat severe respiratory and systemic diseases induced by RNA viruses with a high unmet medical need, such as influenza, COVID-19, hantavirus pulmonary syndrome (HPS) and dengue fever. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response in RNA viruses. Zapnometinib has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. The Company is actively enrolling patients in a Phase II study to evaluate efficacy in hospitalized patients with COVID-19.  Top-line results are expected by the end of Q2 2022. A Phase II study in influenza is currently in preparation, as are further Phase II and III studies in COVID-19. The company received an FDA-Orphan-Drug Designation for the treatment of Hantavirus Infections.  A pipeline of follow-on compounds is actively pursued in early preclinical development. The Company owns 11 patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for antiviral therapies. The patent life runs through 2041.

Atriva is looking for a larger series B financing to support the development program of the lead asset, the platform and to realize a number of inflection points within the next two years.

www.atriva-therapeutics.com

Enbiosis Biyoteknoloji

The future of health is hidden in your microbiome and we at ENBIOSIS guide you to find what is hidden in your guts.

Producing scientific inventions, products, and services by using microbiome organisms, we aim to improve the quality of human health. With our artificial intelligence-powered technologies, we analyze the human gut microbiome in order to provide personalized health solutions that cover a special microbiome diet program and prebiotics.

www.enbiosis.com/

Hoba Therapeutics ApS

At Hoba Therapeutics we are a dedicated team with world-class expertise in pain and the development of biopharmaceuticals.

Our goal is to develop novel biopharmaceuticals for the relief, prevention, and treatment of Chronic Pain and Hearing Loss

www.hobatherapeutics.com/

Iama Therapeutics S.r.l.

At IAMA Therapeutics, a series-A pharmaceutical company, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of individuals suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children and adults suffering from neurological conditions and provide their families with the support they need.

We have developed a platform to identify and advance diverse classes of small molecules to selectively target cation chloride cotransporters (CCCs) and other therapeutic targets relevant to treating central nervous system disorders.

NKCC1 mediates the coupled movement of chloride with potassium and sodium across the cell membrane with essential roles in physiological processes, including modulating neuronal excitability. High NKCC1 activity contributes to maintaining an elevated intracellular chloride concentration such that GABA (γ-aminobutyric acid), the principal inhibitory neurotransmitter in mature neurons under physiological conditions, stimulates chloride efflux and produces depolarizing and excitatory outward currents in immature neurons. The activity of NKCC1 increases also in several pathological conditions; this is why NKCC1 inhibition shows great potential in treating idiopathic and secondary forms of autism (autism spectrum disorder -ASD-), refractory epilepsy, and other neurological disorders.

We understand our job responsibilities and recognize the value of our actions in everything we do. This is why our core values root in excellence, innovation, integrity, equality, respect for diversity, and sustainability of our future generations.

www.iamatherapeutics.com/

Kither Biotech S.r.l.

Kither Biotech is a biopharmaceutical company developing signal transduction modulators for the treatment of rare respiratory diseases.

In recent years, Kither has focused its first-line activities on cystic fibrosis, a rare genetic disease that causes persistent lung infections and, over time, limits its sufferers’ ability to breathe. Kither has developed a small peptide as cAMP modulator, KIT2014, that the European Medicines Agency has designated as an orphan drug.

The company’s product portfolio also includes KITCL27, a small molecule PI3K inhibitor being developed as a prodrug for the treatment of Idiopathic Pulmonary Fibrosis.

kitherbiotech.com/

PDC*line Pharma SA

PDC*line Pharma is a clinical-stage spin-off of the French Blood Bank that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma has initiated a clinical development in lung cancer with a new candidate (PDC*lung) and neoantigens (PDC*neo).

PDC*line is the only cell line of ready-to-use Dendritic Cells for therapeutic use. It is loaded with synthetic peptides derived from tumor antigens, irradiated, and can be stored frozen for years. After thawing, it is injected to activate in vivo a potent cytotoxic anti-tumor CD8+ T-cell response. The product comes in the form of 3 candidates:

•    PDC*mel: our first candidate for melanoma completed a first-in-human phase Ib trial in 2017, demonstrating the safety of the product, the ab-sence of allogeneic rejection and its biological activity. The results of the trial have been pub-lished in the Oncoimmunology journal in 2020.
•    PDC*lung: our leading candidate for non-small-cell lung cancer (NSCLC) targets widely ex-pressed shared antigens (including cancer/testis antigens). A phase Ib/II trial on 64 patients evalu-ating its safety, biological activity, and preliminary clinical activity, with and without anti-PD1, is cur-rently on-going.
•    PDC*neo: is currently being developed at the preclinical stage.

PDC*line Pharma comprises a team of 27 persons based in Belgium and France. The company has raised nearly €52M. The last rounds have been led by the Asian leading VC Korean Investment Partners.
In March 2019, PDC*line Pharma granted an exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercializa-tion of PDC*lung cancer vaccine for lung cancer. The total deal value is €108M (123M$) plus royalties on net sales in Asia.

www.pdc-line-pharma.com

Rising stars session

MESOX LTD

Profile coming soon...